Free Trial

400,000 Shares in Grail, Inc. (NASDAQ:GRAL) Acquired by Newtyn Management LLC

Grail logo with Medical background

Newtyn Management LLC bought a new stake in Grail, Inc. (NASDAQ:GRAL - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 400,000 shares of the company's stock, valued at approximately $7,140,000. Grail comprises about 1.2% of Newtyn Management LLC's portfolio, making the stock its 24th biggest holding. Newtyn Management LLC owned 1.19% of Grail as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in GRAL. FNY Investment Advisers LLC acquired a new position in shares of Grail during the fourth quarter worth about $26,000. State of Tennessee Department of Treasury purchased a new stake in shares of Grail during the fourth quarter worth about $28,000. Lindbrook Capital LLC purchased a new stake in shares of Grail during the fourth quarter worth about $28,000. Sterling Capital Management LLC bought a new stake in Grail in the fourth quarter valued at about $29,000. Finally, Wellington Shields Capital Management LLC bought a new stake in Grail in the fourth quarter valued at about $33,000.

Insider Buying and Selling

In other news, CFO Aaron Freidin sold 1,816 shares of the firm's stock in a transaction dated Friday, March 7th. The stock was sold at an average price of $31.20, for a total value of $56,659.20. Following the sale, the chief financial officer now directly owns 335,170 shares of the company's stock, valued at approximately $10,457,304. This trade represents a 0.54% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Robert P. Ragusa sold 94,035 shares of Grail stock in a transaction dated Friday, May 2nd. The stock was sold at an average price of $33.93, for a total value of $3,190,607.55. Following the sale, the chief executive officer now directly owns 734,627 shares in the company, valued at approximately $24,925,894.11. This trade represents a 11.35% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 194,948 shares of company stock worth $6,583,130. Corporate insiders own 1.85% of the company's stock.

Grail Price Performance

NASDAQ:GRAL traded down $2.75 during trading hours on Monday, reaching $37.16. The company's stock had a trading volume of 587,681 shares, compared to its average volume of 1,254,566. The company has a market cap of $1.31 billion and a price-to-earnings ratio of -0.61. Grail, Inc. has a one year low of $12.33 and a one year high of $63.99. The business's 50-day moving average is $30.01 and its 200-day moving average is $26.75.

Grail (NASDAQ:GRAL - Get Free Report) last issued its quarterly earnings data on Tuesday, May 13th. The company reported ($3.10) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($4.03) by $0.93. The business had revenue of $31.84 million during the quarter, compared to the consensus estimate of $35.80 million. On average, sell-side analysts predict that Grail, Inc. will post -15.15 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on GRAL. Canaccord Genuity Group upped their target price on Grail from $32.00 to $43.00 and gave the company a "buy" rating in a report on Wednesday, May 14th. Morgan Stanley increased their price objective on Grail from $16.00 to $20.00 and gave the company an "equal weight" rating in a research report on Tuesday, March 18th.

View Our Latest Analysis on Grail

About Grail

(Free Report)

GRAIL, Inc operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T.

Recommended Stories

Institutional Ownership by Quarter for Grail (NASDAQ:GRAL)

Should You Invest $1,000 in Grail Right Now?

Before you consider Grail, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Grail wasn't on the list.

While Grail currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

ACT FAST! Congress Is POURING Into This Stock
The Hottest AI Stock You Haven’t Bought Yet
This $13 Trillion Energy Breakthrough Will Make Millionaires

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines